Overview
- SAIDS CEO Khalid Galant confirmed that an out‑of‑competition urine sample taken on 10 April returned an adverse analytical finding for an anabolic steroid from the 18‑year‑old Sharks‑contracted prop.
- Pratt has formally requested B‑sample testing and no hearing, charge or sanction has been set while the standard anti‑doping process runs its course.
- The Sharks have declined further comment, saying the matter is confidential as Pratt recovers from foot surgery sustained on 27 April and follows a roughly six‑month rehabilitation plan.
- If the B‑sample confirms the steroid finding, Pratt could face a ban of up to four years under anti‑doping rules, though any suspension would only take effect after a charge, adjudication and any plea or appeal.
- The case highlights SAIDS’ targeted testing work at youth camps and keeps attention on doping enforcement in South African rugby as testing capacity and past suspensions shape public scrutiny.